Cannabis Australia PTY Ltd to enable domestic cultivation and production of medical cannabis for patients while serving as a distribution hub for other jurisdictions in Asia-Pacific.
On May 24, 2018, the Canopy Shares commenced trading on the NYSE under the ticker symbol “CGC”.
On May 28, 2018, Canopy announced the appointment of Dr. Mark Ware as Chief Medical Officer, effective July 1, 2018.
On May 30, 2018, Canopy acquired Daddy Cann Lesotho PTY Ltd., which holds a licence to cultivate, manufacture, supply, hold, import, export and transport cannabis and its resin in the Kingdom of Lesotho, in exchange for 666,362 Canopy Shares and, subject to meeting certain milestones, up to an additional 333,281 Canopy Shares.
On June 11, 2018, Canopy announced that it had entered into an agreement with BI to terminate Canopy’s licensing arrangement with BI. 1955625 Ontario Inc. (formerly Bedrocan Canada Inc.) agreed to cease the production and sale of Bedrocan products by December 31, 2018.
On June 20, 2018, Canopy closed an offering of C$500 million aggregate principal amount of 4.25% convertible senior notes due 2023 (the “Canopy Notes”) pursuant to an indenture (the “Indenture”) dated June 20, 2018 among Canopy, GLAS Trust Company LLC and Computershare Trust Company of Canada. The initial conversion rate for the Canopy Notes is 20.7577 Canopy Shares per C$1,000 principal amount of Canopy Notes, equivalent to an initial conversion price of approximately C$48.18 per share. On June 22, 2018, Canopy closed an additional C$100 million aggregate principal amount of Canopy Notes pursuant to the exercise in full of the over-allotment option. GCILP purchased $200 million in Canopy Notes in the offering.
On June 27, 2018, Canopy announced that Mark Zekulin had been appointed to the role of President andCo-Chief Executive Officer of Canopy.
On July 5, 2018, Canopy acquired thenon-controlling 33% interest in BC Tweed in exchange for $1 million in cash and 13,293,968 Canopy Shares, including C$20 million worth of Canopy Shares in connection with an option to acquire certain future infrastructure in California, United States.
On July 5, 2018, Canopy acquired Spectrum Colombia in exchange for 1,193,237 Canopy Shares and upon the satisfaction of four further milestones, up to 524,576 Canopy Shares on the completion of each milestone In addition, Canopy will issue additional Canopy Shares on July 4, 2023 in an amount equal to 4% of the fair market value of Canopy LATAM, provided that all of the milestones have been completed by such date.
On July 5, 2018, Canopy acquired Canindica, a company controlled by Antonio Droghetti, in exchange for 595,184 Canopy Shares and upon the satisfaction of four milestones, additional Canopy Shares at each milestone valued at C$9,333,333. In addition, Canopy will issue additional Canopy Shares on July 4, 2023 in an amount equal to 6% of the fair market value of Canopy LATAM, provided that all of the milestones have been completed by such date.
On August 7, 2018, Canopy completed a plan of arrangement to acquire thenon-controlling interests in CHI, including its wholly-owned subsidiary Canopy Animal Health Inc. in exchange for 3,076,941 Canopy Shares and 568,005 replacement options.
On August 9, 2018, Canopy acquired the remaining outstanding shares of its Chileanin-market entity, Spectrum Cannabis Chile SpA in exchange for US$750,000.
C-5